Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Progress Report: EAMS A Limited Success But Could Do Better

Executive Summary

The UK's Early Access to Medicines Scheme (EAMS) has been operational for two years, along with a "promising innovative medicine" (PIM) designation, to give patients timely access to new drugs for serious diseases before they are approved. The system has now been independently reviewed and Scrip talks to those in the industry that have first-hand experience of the process.

You may also be interested in...

Brexit Vote Dismays UK Pharma, Triggers Calls To Leverage NHS As Offset

The UK now urgently needs to leverage the uniqueness of its National Health System to attract global pharma companies and offset the anti-business message contained in Thursday's Brexit vote, and the government's imminent accelerated access review needs to contain the first elements of that objective, according to the Association of the British Pharmaceutical Industry.

First UK patients to get Merck's Keytruda after landmark early access decision

Merck says its new drug for advanced melanoma, pembrolizumab, is expected to be made available in the UK very soon, after it became the first product to gain a scientific opinion under the UK's Early Access to Medicines Scheme (EAMS).

BMS Opdivo designation a boost for UK early access scheme

The award of the UK's third "Promising Innovative Medicine" (PIM) designation, to Bristol-Myers Squibb's drug for advanced melanoma Opdivo (nivolumab), is clearly good news for the company and for patients. But it is also something of a vote of confidence in the UK's Early Access to Medicines Scheme (EAMS), amid concerns that the costs of the scheme could deter some companies from using it.

Related Content


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts